Advancements in proteogenomics for preclinical targeted cancer therapy research

被引:0
|
作者
Yuying Suo [1 ,2 ]
Yuanli Song [1 ]
Yuqiu Wang [1 ,3 ]
Qian Liu [1 ]
Henry Rodriguez [4 ]
Hu Zhou [1 ]
机构
[1] Department of Analytical Chemistry, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences
[2] University of Chinese Academy of Sciences
[3] Department of Otolaryngology, Eye & ENT Hospital, Fudan University
[4] Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of
关键词
D O I
暂无
中图分类号
R73-36 [治疗实验];
学科分类号
摘要
Advancements in molecular characterization technologies have accelerated targeted cancer therapy research at unprecedented resolution and dimensionality. Integrating comprehensive multi-omic molecular profiling of a tumor, proteogenomics, marks a transformative milestone for preclinical cancer research. In this paper, we initially provided an overview of proteogenomics in cancer research,spanning genomics, transcriptomics, and proteomics. Subsequently, the applications were introduced and examined from different perspectives, including but not limited to genetic alterations, molecular quantifications, single-cell patterns, different post-translational modification levels, subtype signatures,and immune landscape. We also paid attention to the combined multi-omics data analysis and pancancer analysis. This paper highlights the crucial role of proteogenomics in preclinical targeted cancer therapy research, including but not limited to elucidating the mechanisms of tumorigenesis, discovering effective therapeutic targets and promising biomarkers, and developing subtype-specific therapies.
引用
收藏
页码:56 / 76
页数:21
相关论文
共 50 条
  • [1] Recent advancements in the targeted therapy of metastatic kidney cancer
    Yazici, Sertac
    Kiziloz, Halil
    Ozen, Haluk
    UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY, 2011, 10 (03): : 41 - 51
  • [2] Advancements in Human Breast Cancer Targeted Therapy and Immunotherapy
    Bou-Dargham, Mayassa J.
    Draughon, Sophia
    Cantrell, Vance
    Khamis, Zahraa I.
    Sang, Qing-Xiang Amy
    JOURNAL OF CANCER, 2021, 12 (23): : 6949 - 6963
  • [3] Advancements in combining targeted therapy and immunotherapy for colorectal cancer
    Singh, Manisha
    Morris, Van Karlyle
    Bandey, Irfan N.
    Hong, David S.
    Kopetz, Scott
    TRENDS IN CANCER, 2024, 10 (07) : 598 - 609
  • [4] Precision oncology: Using cancer genomics for targeted therapy advancements
    Avci, Cigir Biray
    Bagca, Bakiye Goker
    Shademan, Behrouz
    Takanlou, Leila Sabour
    Takanlou, Maryam Sabour
    Nourazarian, Alireza
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2025, 1880 (01):
  • [5] Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer
    Feng Ye
    Saikat Dewanjee
    Yuehua Li
    Niraj Kumar Jha
    Zhe-Sheng Chen
    Ankush Kumar
    Tapan Vishakha
    Saurabh Kumar Behl
    Hailin Jha
    Molecular Cancer, 22
  • [6] Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer
    Ye, Feng
    Dewanjee, Saikat
    Li, Yuehua
    Jha, Niraj Kumar
    Chen, Zhe-Sheng
    Kumar, Ankush
    Vishakha
    Behl, Tapan
    Jha, Saurabh Kumar
    Tang, Hailin
    MOLECULAR CANCER, 2023, 22 (01)
  • [7] Proteogenomics: advances in cancer antigen research
    Kanaseki, Takayuki
    Torigoe, Toshihiko
    IMMUNOLOGICAL MEDICINE, 2019, 42 (02) : 65 - 70
  • [8] Advancements in Preclinical Models of Pancreatic Cancer
    Salu, Philip
    Reindl, Katie M.
    PANCREAS, 2024, 53 (02) : e205 - e220
  • [9] Recent advancements in PARP inhibitors-based targeted cancer therapy
    Zhou, Ping
    Wang, Justin
    Mishail, Daniel
    Wang, Cun-Yu
    PRECISION CLINICAL MEDICINE, 2020, 3 (03) : 187 - 201
  • [10] Preclinical models for bladder cancer therapy research
    Ertl, Iris
    Shariat, Shahrokh F.
    Berger, Walter
    Englinger, Bernard
    CURRENT OPINION IN UROLOGY, 2024, 34 (04) : 244 - 250